Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

NCT03785067 is registered in ClinicalTrials.gov with The George Institute as lead sponsor.

NCT NCT03785067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03785067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
Lead sponsor
The George Institute
Phase
Phase 3
Overall status
Terminated
Start date
February 27, 2020
Completion date
February 3, 2021
Enrollment
1 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral small vessel diseases, cognitive decline, dementia, vascular, hypertension, intracerebral hemorrhage, stroke hemorrhagic